Literature DB >> 24291998

[Gastrointestinal dysfunction has important implications for plasma L-dopa concentrations in Parkinson's disease].

Hirokazu Doi1, Ryuji Sakakibara, Masahiko Kishi, Yohei Tsuyuzaki, Fuyuki Tateno, Shigekazu Hirai.   

Abstract

Gastrointestinal motility dysfunctions including anorexia, nausea, heartburn, bloating, etc. are common and frequent complication of Parkinson's disease (PD). Degeneration of enteric nerves system is supposed to be a pathogenesis of these symptoms. Impairment of gastric emptying (GE) leads to retardation of the drug delivery from stomach to jejunum, so that PD patients with GE impairment show the delayed elevation of plasma L-dopa concentration. Disturbance of L-dopa absorption will result in wearing-off and delayed-on, and these are called motor fluctuation. In our investigation, 69% of PD patients who exhibited delayed elevation of plasma L-dopa concentration complicated GE impairment, whereas only 22% of patients with normal L-dopa level showed GE retardation (p = 0.0044, χ(2)-test). Serotonin 5-HT4 agonist and dopamine D2 antagonist are useful to improve GE impairment in PD. These drugs stimulate the postganglionic cholinergic fiber to release acetylcholine amongst the enteric nerves system and facilitate the gastrointestinal tract. Rikkunshi-to, dietary herbal medicine, is also administered to ameliorate gastrointestinal symptoms in PD. Rikkunshi-to is reported to improve erratic GE and reduce the variation of plasma L-dopa level. Recently, intestinal continuous L-dopa administration is expected as the potential solution for L-dopa induced motor fluctuation in advanced PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24291998     DOI: 10.5692/clinicalneurol.53.1382

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  1 in total

1.  Correlation Between Lacunae and the Wearing-off Phenomenon in Parkinson's Disease.

Authors:  Meimei Zhang; Huimin Chen; Genliang Liu; Xuemei Wang; Zhan Wang; Tao Feng; Yumei Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2022-01-11       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.